Evidence map›Paper›PMID 40528393›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Discrepancies in assessing intellectual disability levels in adults with Down syndrome: Implications for dementia diagnosis.

Laura Del Hoyo Soriano, Katja Sandkühler, Laura Videla, Bessy Benejam, Maria Carmona-Iragui, Elisabeth Wlasich, Julia Kustermann, Isabel Barroeta, Lídia Vaqué-Alcázar, Íñigo Rodríguez-Baz and 12 more

Abstract readMulticenter Study
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Changes in serum β-synuclein precede blood biomarkers of Alzheimer pathology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Laura Del Hoyo SorianoSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.ORCID 0000-0003-4372-1599
Katja SandkühlerDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.ORCID 0009-0000-7117-2270
Laura VidelaSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Bessy BenejamSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Maria Carmona-IraguiSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Elisabeth WlasichDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Julia KustermannDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Isabel BarroetaSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Lídia Vaqué-AlcázarSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Íñigo Rodríguez-BazSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Alexandre BejaninSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Susana FernándezBarcelona Down Medical Center, Fundació Catalana de Síndrome de Down, Barcelona, Spain.
Javier ArranzSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Jose Enrique Arriola-InfanteSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Lucia Maure-BlesaSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Aida San JuanSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.
Georg NüblingDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Olivia WagemannDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Anna StockbauerDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Jason HassenstabDepartments of Neurology and Psychological & Brain Sciences, Washington University in St. Louis, St. Louis, Missouri, USA.
Johannes LevinDepartment of Neurology, University Hospital, Ludwig-Maximilians-University (LMU) Munich, Munich, Germany.
Juan ForteaSant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Barcelona, Spain.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
DS-ARC: A Remote Digital Cognitive Assessment for Down Syndrome-Associated Alzheimer's DiseaseR01AG081394 · NIA · WASHINGTON UNIVERSITY · PI Jason J Hassenstab · 2023 to 2026
$6.0M
Biological Correlates of Alzheimer in Down Syndrome.R21AG056974 · NIA · UNIVERSITY OF DENVER (COLORADO SEMINARY) · PI GRANHOLM-BENTLEY, ANN-CHARLOTTE ESTHER · 2017 to 2018
$414k
Alzheimer's Association AARG-22-923680 to A.BAlzheimer's Association AARG-22-973966 to M.C-ICarlos III Health Institute CM23/00291Carlos III Health Institute INT21/00073Carlos III Health Institute PI20/01473Carlos III Health Institute PI22/00307 to ABCarlos III Health Institute PI22/00785 to M.C-ICarlos III Health Institute PI23/01786 to J.FCarlos III Health Institute and European Union, Miguel Servet Program CP20/00038 to A.BCarlos III Health Institute and European Union, Miguel Servet Program CP24/00112 to L.D.H.SCarlos III Health Institute and European Union Río-Hortega program CM22/00052 to I.R.B.Carlos III Health Institute and European Union Río-Hortega program CM22/00219 to J.E.A.I.Carlos III Health Institute and European Union Río-Hortega program CM23/00291 to L.M.BCarlos III Health Institute, Sara Borrell CD23/00235 to L.VCarlos III Health Institute, Sara Borrell CM22/00052 to I.R.-BCarlos III Health Institute, Sara Borrell CM22/00219 to J.E.A.-ICarlos III Health Institute, Sara Borrell CM23/00291 to L.M.BCentro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas Program1Departament de Salut, Generalitat de Catalunya SLT006/17/00119Department de Salut de la Generalitat de Catalunya Pla Estrategic de Recerca I Innovació en Salut LT006/17/00119 to J.FDeutsche Forschungsgemeinschaft DFG, German Research Foundation, under Germany's Excellence Strategy within the framework of the Munich Cluster for Systems Neurology EXC2145SyNergy-ID390857198Fundación Tatiana Pérez de Guzmán el Bueno IIBSP-DOW-2020-151 to J.FJérôme Lejeune Foundation 2326 - GRT-2024A to L.D.H.SJérôme Lejeune Foundation AARG-22-923680 to A.BJérôme Lejeune Foundation AARG-22-973966 to M.C-ILa Caixa FoundationNIH HHS R01AG056850NIH HHS R01AG061566NIH HHS R01AG081394NIH HHS R21AG056974NIH HHS R61AG066543 to J.FNIH HHS U01AG024904Research and Innovation Framework Program H2020-SC1-BHC-2018-2020 to J.FT21RS Scientific Exchange Grant to K.SVERUM Foundation
6 · The paper itself

Abstract

introductionCut-offs derived from baseline cognitive assessments, stratified by intellectual disability (ID) level, have been proposed to diagnose symptomatic Alzheimer's disease (AD) in Down syndrome (DS). However, discrepancies in ID classification risk misclassification when applying cut-offs across sites.

methodsThis dual-center cohort study included 673 adults with mild to moderate ID at different AD stages. We assessed ID classification discrepancies across sites and the impact on Cambridge Cognitive Examination for Older Adults with Down's Syndrome (CAMCOG-DS) cut-offs for AD dementia diagnosis derived from receiver operating characteristic analysis.

resultsInter-rater agreement for ID level classification was 95% within sites but 60% between sites. While CAMCOG-DS score distributions in the whole cohort were similar across sites, ID classification discrepancies caused higher cut-offs in Barcelona for mild and moderate ID compared to Munich. Applying site-specific cut-offs to another cohort reduced sensitivity and specificity. DISCUSSION: Standardizing ID classification is critical for generalizable cut-offs to accurately diagnose AD dementia based on neuropsychological assessments in DS. HIGHLIGHTS: CAMCOG-DS cut-offs by intellectual disability level classify dementia in Down syndrome. ID classification discrepancies between sites impact CAMCOG-DS diagnostic cut-offs. Applying site-specific cut-offs to other cohorts reduces sensitivity and specificity. Standardized ID classification is essential for generalizable cognitive cut-offs. Use site-specific cut-offs until ID classification is standardized.

Indexed as

Alzheimer DiseaseDementiaDown SyndromeIntellectual DisabilityAgedCohort StudiesFemaleHumansMaleMiddle AgedNeuropsychological TestsAD21Alzheimer's diseaseCambridge Cognitive Examination for Older Adults with Down Syndromecut‐off pointsdementiadiagnostic performanceDown Alzheimer Barcelona Neuroimaging InitiativeDown syndromeDown syndrome–associated Alzheimer's diseaseintellectual disability

Identifiers

PMID40528393
PMCPMC12173952

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.